NATIONAL HARBOR, MARYLAND — Cilcare, a French-US biopharmaceutical company specializing in auditory science, announced a series of U.S. investments at the SelectUSA Investment Summit 2026, including plans for a clinical trial of its lead tinnitus drug candidate at Massachusetts General Hospital, expanded preclinical capacity through its partner CBSET, and the launch of a U.S....
No actionable clinical change at this time; the tinnitus trial is only planned and no results are available yet.
A planned clinical trial for a novel tinnitus drug candidate at a major academic center signals growing pharmaceutical investment in tinnitus treatment, an area with no currently approved pharmacological therapy.
- 01Cilcare is expanding U.S. operations via a partnership with CBSET, a contract research organization.
- 02A clinical trial of Cilcare's lead tinnitus drug candidate is planned at Massachusetts General Hospital.
- 03Announcement made at SelectUSA Investment Summit 2026—primarily an investor-facing event.
- 04No trial results or drug efficacy data are presented.
- 05Tinnitus remains an area with no FDA-approved pharmacological treatments.
Cilcare has a lead tinnitus drug candidate that is planned for clinical trial evaluation at Massachusetts General Hospital.
press releaseunclear